



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification³ : A61K 31/155	A1	(11) International Publication Number: WO 85/01876 (43) International Publication Date: 9 May 1985 (09.05.85)
(21) International Application Number: PCT/AU84/00215 (22) International Filing Date: 22 October 1984 (22.10.84) (31) Priority Application Number: PG 2011 (32) Priority Date: 24 October 1983 (24.10.83) (33) Priority Country: AU (71) Applicant (for all designated States except US): LOCK-LEY SERVICES PTY. LTD. [AU/AU]; 32 Highwood Drive, Glen Waverley, VIC 3150 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only) : TOMLINSON, Rod-erick, Peter, John [AU/AU]; 32 Highwood Drive, Glen Waverley, VIC 3150 (AU). (74) Agent: EDWD. WATERS & SONS; 50 Queen Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AT (European patent), AU, BE (Eu-ropean patent), CH (European patent), DE (Euro-pean patent), FR (European patent), GB (European patent), JP, LU (European patent), NL (European pa-tent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: FOAMABLE BIOCIDAL COMPOSITION (57) Abstract A biocidal composition comprising: (a) an alcoholic chlorhexidine solution, (b) from .1 to 20% w/w of a quick breaking foaming agent, (c) from 3 to 30% w/w of an aerosol propellant and optionally (d) a corrosion inhibitor.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

FOAMABLE BIOCIDES COMPOSITIONBACKGROUND OF THE INVENTION

The present invention relates to a foamable biocidal composition.

5 The chemical control of bacteria and viruses is assuming increasing importance in the hospital and medical environment. Outbreaks of infections such as Methycylin resistant Staph Aureus are causing illness, death and even temporary closure of wards in some hospitals.

10 This situation has been exacerbated by the failure of many bacteria to respond to conventional antibiotics. Accordingly, the need for effective control of bacterial and virus organisms is assuming greatly increased significance.

15 In the case of hand and skin disinfection a biocidal agent needs to kill the widest possible range of microorganisms in the least possible time without toxicity, irritation or other hazard and have a long shelf life.

20 Typical of these biocides are chlorine, iodophors and organic chemicals such as chlorhexidine which are commonly employed in hospitals and surgeries. The most widely accepted form of safe, effective biocide is chlorhexidine gluconate in aqueous ethanol. A full discussion of this product appears in the paper entitled
25 "Detergents compared with each other and with antiseptics as skin 'degerminating agents'" by H.A. Lily et al in Journal of Hygiene (U.K.). Further technical disclosure of the product appears in Australian Patents Nos. 157,758 and 222,033. Conventionally, chlorhexidine is commercially
30 supplied in a pump pack or manufactured by the hospital pharmacist as required.

Unfortunately, however, in use alcoholic chlorhexidine has inherent difficulties including the following:

35 (1) Openable bottles of alcoholic chlorhexidine are subject to contamination both at the time of fitting the pump head and when the pump is being operated.



-2-

(2) The 60-70% aqueous ethanol system is highly flammable. Spillage from the plastic bottle or dispenser at any time could result in a fire.

5 (3) The mist as applied from pump dispensers is a highly flammable mist. This could be highly dangerous since it is being sprayed directly onto the skin.

(4) The spray mist does not confine itself to the target area, wastage occurs due to overspray.

10 (5) The alcoholic lotion as sprayed on the skin is difficult to control due to its low viscosity. It tends to run off the skin and evaporate rapidly before being evenly distributed.

(6) The shelf life of pump packs of a volatile fluid such as alcohol is restricted by the fact that they do not seal the pack perfectly and evaporation can occur over a period of time.

(7) The spray or lotion product is messy to use since once one hand has been sprayed it must become contaminated as the pack is held to spray the other hand.

20 Accordingly, it is well known that chlorhexidine must be formulated very carefully to optimise its biocidal performance.

DESCRIPTION OF THE INVENTION

25 With the above difficulties in mind, the present invention provides an improved composition containing alcoholic chlorhexidine in aerosol form which is easy and safe to use. In this respect, extensive research over several years was necessary on a variety of differing types compositions before the viability of an aerosol type became apparent.

30 Accordingly, a biocidal composition is provided comprising:

- (a) an alcoholic chlorhexidine solution
- (b) from .1 to 20% w/w of a quick break foaming agent
- 35 (c) from 3-30% w/w of an aerosol propellant and



-3-

optionally

(d) a corrosion inhibitor

The inclusion of a corrosion inhibitor is necessary where the composition is stored in metal containers which are typical of tin plate or aluminium to counteract the corrosive nature of chlorexidine formulations. However, if the container is to non metal e.g. glass the inclusion of a corrosion inhibitor is not necessary.

As stated the composition of the invention is an aerosol form. This is most appropriate for a biocide as it avoids or minimizes the conventional defects of contamination and spillage. Pressurized aerosol containers are readily available, have been extensively tested and are well accepted.

PREFERRED FEATURES OF THE INVENTION

In an effort to minimize the aforementioned difficulty of overspray and early evaporation, a foaming agent was included, more particularly of a quick break foam variety. This has the ability of providing a thick ball of foam which disintegrates easily when spread. Proper coverage can be effected to the surface to be cleansed without premature evaporation. A general discussion of quick break foams can be found in Australian Patent 463,216. In a preferred embodiment of the present invention, a particular quick breakfoaming agent has been developed which has not been previously disclosed in this context.

This composition comprises

(a) an aliphatic alcohol preferably in amounts from 40-90% w/w composition more preferably 55-70 % w/w and most preferably 60% w/w,

(b) water preferably in amounts from 10-40 % w/w

(c) a fatty alcohol preferably in amounts from 5-10% w/w

and

(d) a surface active agent preferably an ethoxylated



-4-

sorbitan ester (as emulsifier); typically in amounts from .1-15% w/w.

From the viewpoint of performance it was known from the paper of H.A. Lilly et al that aqueous ethanol of approximately 70% w/w ethanol concentration is the best vehicle for chlorhexidine and this is the preferred form for use in the present composition.

It is also well known that a base formulation of chlorhexidine in aqueous ethanol tends to degrease and dry out the skin when used regularly (e.g. 40 times per shift) in the hospital environment. Thus, an emollient is optionally incorporated which would help prevent dehydration of the skin without hindering the performance of chlorhexidine. Emollients which are particularly preferred are lanolin and polyols selected from glycerol, propylene glycerol, sorbitol and low molecular weight polymers thereof. Other examples of emollients are vinyls alcohol and polyvinyl pyrrolidone.

When considering the preferred requirement for 70% w/w ethanol, it was found that the composition may have an effect on the solubility characteristics of other additive e.g. fatty alcohols, lanolin and organic acid salts. It is believed the other additives react with the chlorhexidine causing it to be, to some extent, either precipitated or inactivated. Nevertheless, such compositions are still found to be useful.

The chlorhexidine component will normally be present in amounts of from .1-10% w/w though larger concentrations were found to be possible but with deleterious effects on the efficiency of entire system. Preferred forms of chlorhexidine are as a gluconate, diacetate, hydrochloride or other salts thereof.

Care should be taken to select a propellant most compatible to the entire system and in this respect the propellant is preferably selected from a group comprising propane, butane, dichloro difluoro methane, dichloro tetra fluoro ethane, octafluoro cyclo butane. As mentioned the



-5-

propellant should be presenting amounts from 3 - 30% w/w' though preferably from about 5 to 15% w/w and more preferably from 8 to 10% w/w.

5 Where the container is metal it is necessary to incorporate a corrosion inhibitor. This became apparent when researching the invention as several working formulation were achieved which however were found to corrode tin plate or aluminium containers at extraordinary rates resulting in short shelf lives. Typical corrosions
10 inhibitors were organic acid salts more preferably sorbic acid, benzoic acid, sodium benzoate and potassium sorbate.

These inhibitors are preferably present in amounts of from .1 to 15% wt and more preferably for .1 to 3% w/w.

Thus, a typical formulation of the present invention
15 is as follows:



-6-

		<u>% w/w</u>
	Propellant (e.g. propane, butane, dichloro difluoro methane, dichloro tetra fluoro ethane, octafluoro cyclo butane and mixtures thereof)	3 - 30
5	Chlorhexidine (as gluconate, diacetate hydrochloride and mixtures thereof, & other salts)	.1 - 10
	Fatty alcohol (e.g. cetyl, stearyl, lauryl, myristyl, palmityl and mixtures thereof)	.5 - 10
10	Aliphatic alcohol (e.g. methyl, ethyl, isopropyl, butyl and mixtures thereof)	40 - 90
	Water	10 - 40
	Polyol (e.g. glycerol, propylene glycol, sorbitol & low molecular weight polymers thereof)	1 - 10
15	Organic acid salt (e.g. sorbic acid, benzoic acid)	.1 - 15
	Surface active agent (e.g. ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates, fatty alcohol ethoxylates)	.1 - 15
20		



-7-

		<u>% w/w</u>
	<u>Particularly Preferred formulations</u>	
	Chlorhexidine gluconate 20%	5.0
	Cetyl stearyl alcohol	2.5
	Ethoxylated sorbitan monostearate	0.5
5	Propylene glycol	3.0
	Ethyl alcohol (95%)	57.0
	Sodium benzoate	0.2
	Purified water	22.8
	Dichloro difluoro methane)	
10	Dichloro tetrafluoro ethane) blend	<u>9.0</u>
		100.0
		<hr/>
	Chlorhexidine diacetate	1.0
	Myristyl alcohol	3.0
	Ethoxylated cetylalcohol	0.8
	Glycerol	2.5
15	Isopropyl alcohol	60.0
	Potassium sorbate	0.3
	Purified water	25.4
	Butane/propane	<u>7.0</u>
		100.0
		<hr/>
20	Chlorhexidine gluconate 20%	5.0
	Myristyl alcohol	3.0
	Glycerol	2.5
	Ethoxylated myristyl alcohol	0.8
	Ethyl alcohol 95%	58.0
254	Postassium sorbate	1.0
	Purified water	20.3
	Dichloro difluoro methane)	
	Dichloro tetrafluoro ethane)	<u>10.0</u>
		100.0
		<hr/>



-8-

The following are details of tests which were carried out of such formulations in which the formulation is identified by the Trade mark HEXIFOAM.

TEST A

5 A series of In-vitro tests were performed on "Hexifoam" to determine the efficacy of the Chlorhexidine within this formulation.

10 The tests were designed to establish whether any loss of biocidal activity of the chlorhexidine was occurring. Comparative evaluations were also performed utilizing "Hexifoam" (without Chlorhexidine) and unformulated non-alcohol Chlorhexidine Gluconate Standard.

15 The product was evaluated in a suspension test based on the principles outlined in BS.3286 under the following test conditions.

Product Dilutions:	1:2 v/v, 1:4 v/v
Contact Time;	1 minute, 2 minutes, 3 minutes 5 minutes
Organism:	<u>Pseudomonas aeruginosa</u> NCTC 6749
Organic Challenge:	10% Sheep Serum
Inoculum Density:	106 - 107 orgs/ml.
Product Diluent:	Distilled Water with 10% Sheep Serum
25 Inactivator:	Nutrient Broth N.2, Lecithin, Tween 80
Temperature:	Ambient



-9-

ResultsTest Organism: Pseudomonas aeruginosa

Sample	Dilution/ Concent- ration	Initial Count per ml	Surviving Organisms per ml.			
			1min	2min	3min	5min
5 Hexifoam	1:2	8.0×10^6	10	10	10	10
Hexifoam without	1:2	8.0×10^6	10	10	10	10
10 Chlorhex- idine						
			1 min	2 mins	3 mins	
Hexifoam	1:4 ¹	3.9×10^6	10	10	10	
Hexifoam without	1:4	3.9×10^6	1,500,000	800,000	500,000	
15 Chlorhex- idine						
Chlorhex- idine	0.25%	5.0×10^6	10	10	10	
Gluconate						

20 Notes

1 At 1:4 dilution of Hexifoam the concentration of Chlorhexidine is 0.25%.

2 ' / ' indicates less than
Less than 10 is the detection
25 sensitivity of the test method
i.e. no surviving organisms
detected.

Conclusion

30 The results have indicated that a dilution of the product Hexifoam of 1:4 v/v continues to demonstrate excellent biocidal properties while the base material without chlorhexidine fails to show any significant



-10-

biocidal properties. This is indicative of little or no loss of activity of the chlorhexidine within the formulation.

5 The comparative tests with Chlorhexidine Gluconate standard at 0.25% confirmed that the biocidal activity under the above test conditions was found to be equivalent.

The product Hexifoam has shown very rapid biocidal action against the organisms Pseudomonas aeruginosa and Staphylococcus aureus (Our Ref N 17,614). Complete kill
10 of the test organisms was achieved within 1 minute in the in-vitro tests performed to date.

TEST B

A sample of "Hexifoam" was received at the laboratory to be evaluated for its biocidal properties
15 against the organism Staphylococcus aureus.

The product was evaluated in a suspension test in accordance with the principles outlined in BS. 3286 under the following test conditions.

20	Product Dilution:	1:2 v/v
	Contact Time:	1 minute, 2 minutes, 5 minutes
	Organism:	Staphylococcus aureus 4163
	Organic Challenge:	10% Sheep Serum
	Inoculum Density:	10^6 orgs/ml.,
25	Product Diluent:	Standard Hard Water - 10% Sheep Serum
	Inactivator:	Nutrient Broth No. 2 Lecithin Tween 80
	Temperature:	Ambient
30	Initial count	1 Min. Final Count per ml *
		2 Mins. 5 Mins.

2.0×10^6	Less than 10	Less than 10	Less than 10
-------------------	--------------	--------------	--------------

The Kill Factor achieved in all cases was greater than 2.0×10^5

* Results presented are Geometric Means of duplicate tests.



- 11

TEST C

The product Hexifoam batch 4073 was evaluated for its biocidal activity using a suspension test based on the principles outlined in British Standard BS.3286. The

5 results obtained are as follows:-

Product: Hexifoam
 Test Organism: C.albicans ATCC 10231
 Product Dilution: 1:2 w/v
 Diluent: Distilled water with 10% sheep serum
 10 Organic Challenge: 10% sheep serum
 Temperature: Ambient
 Contact Time: One Minute
 Inactivator: Nitritent Broth No. 2 (Oxoid) with
 lecithin and tween 80.

15	Initial Count	Final Count	Kill Factor	% Kill
	3.7×10^6	Less than 10	Greater than 3.7 x 105	Greater than 99.99973

Notes

- 20 1. Results presented are geometric means of duplicate results.
2. Kill factor is defined as the ratio of initial count versus final count.
3. A kill factor of 10^4 is regarded as significant
 25 biocidal activity.

TEST D

The product Hexifoam batch 4073 was evaluated for its biocidal activity using a suspension test based on the principles outlined in British Standard BS.3286. The
 30 results obtained are as follows:-



-12-

Product: Hexifoam
 Test Organism: E.coli NCTC 8196
 Product Dilution: 1:2 w/v
 Diluent: Distilled water with 10% Sheep serum
 5 Organic challenge: 10% Sheep serum
 Temperature: Ambient
 Contact Time: One minute
 Inactivator: Nutrient broth No. 2 (Oxoid) with
 lecithin and tween 80.
 10 Initial Count Final Count Kill Factor % Kill
 orgs/ml. orgs/ml.

6.7×10^6	Less than	Greater	Greater than
	10	than	99.99986
		6.7×10^5	

15 Notes:

1. Results presented are geometric means of duplicate results.
2. Kill factor is defined as the ratio of initial count versus final count.
- 20 3. A kill factor of 10^4 is regarded as significant biocidal activity.

TEST E

The product Hexifoam batch 4073 was evaluated for its biocidal activity using a suspension test based on the
 25 principles outlined in British Standard BS.3286. The results obtained are as follows:-

Product: Hexifoam
 Test Organism: S.typhimurium (clinical isolate)
 Product Dilution: 1:2 w/v
 30 Diluent: Distilled water with 10% sheep serum
 Organic Challenge: 10% sheep serum
 Temperature: Ambient
 Contact Time: One Minute
 Inactivator: Nutrient broth No. 2 (Oxoid) with
 35 lecithin and tween 80.



-13-

Initial Count Orgs/ml.	Final Count Orgs/ml.	Kill Factor	% Kill
6.7×10^6	Less than 10	Greater than 6.7×10^5	Greater than 99.99986

Notes

1. Results presented are geometric means of duplicate results.
2. Kill factor as defined as the ratio of initial count versus final count.
3. A kill factor of 10^4 is regarded as significant biocidal activity.

TEST F

The product Hexifoam Batch 4073 was evaluated for its biocidal activity using a suspension test based on the principles outlined in British Standard BS.3286. The results obtained are as follows:-

Product:

Hexifoam

Test Organism:

S.aureus

(Methicillin Resistant, Clinical Isolate)

Product Dilution:

1:2 w/v

Diluent:

Sterile Distilled Water with 10% Sheep Serum.

Temperature:

Ambient

Contact Time:

One Minute

Inactivator:

Nutrient Broth No.2 (Oxoid) with Lecithin and Tween 80.

Initial Count

Final Count

Kill Factor

% Kill

(Orgs/ml.)

4.6 x 10⁶

Less than 10

Greater than 4.6 x 10⁵

Greater than 99.9954%



-14-

Notes:

1. Results presented are geometric means of duplicate results.
2. Kill factor is defined as the ratio of initial count versus final count.
3. A Kill Factor of 10^4 is regarded as significant biocidal activity.

TEST G

The product Hexifoam Batch 4073 was evaluated for its biocidal activity using a suspension test based on the principles outlined in British Standard BS.3286. The results obtained are as follows:-

Product:	Hexifoam		
Test Organism:	T.rubrum (clinical isolate)		
Product Dilution:	1:2 w/v		
Diluent:	Distilled Water with 10% Sheep Serum		
Organic Challenge:	10% Sheep Serum		
Temperature:	Ambient		
Contact Time:	5 minutes		
Inactivator:	Nutrient Broth No.2 (Oxoid) with lecithin and Tween 80		
Initial Count	Final Count	Kill Factor	% Kill
Orgs/ml.	Orgs/ml.		
<hr/>			
1.0×10^7	Less than 10	Greater than 1.0×10^6	Greater than 99.9999

Notes

1. Results presented are geometric means of duplicate results.
2. Kill factor is defined as the ratio of initial count versus final count.



TEST H

Hexifoam was evaluated in our laboratory in a short, preliminary in-vivo trial using various dosages and exposure times against Pseudomonas aeruginosa NCTC 6749.

5 Experimental Design

Two volunteers from our laboratory were used. For the duration of the experiment the hands of the personnel were allowed to be washed only with traditional bar soap. No chlorhexidine based products such as our standard laboratory scrub were used to ensure there was no build up of chlorhexidine on the skin. The time interval between Hexifoam trials was at least three days.

Fresh 24 hour suspension cultures of P.aeruginosa NCTC 6749 were utilised for each trial. Cultures were grown in Wright and Mundy broth (Difco) for 24 hours at 37°C.

One ml. of P.aeruginosa representing at least 1×10^9 cells was applied to the palm of one hand. This was then carefully rubbed over the surface of both hands. No culture was allowed to be dropped from the hands during this operation. If so the trial was declared void at that time, the person washed their hands and the inoculation was repeated after a break of at least two hours. The culture was allowed to dry completely on the hands before application of Hexifoam.

Hexifoam was weighed on to a plastic square and then applied to the hands. This procedure ensured accurate dosage by weight. The Hexifoam was rubbed over the entire surface of the hands. Exposure time was monitored with a stop watch. At the end of the allocated exposure time the hands were placed into 500 ml. of inactivator solution comprising 3% tween 80, 2% lecithin. For one minute the hands were scrubbed in the inactivator solution to release any surviving P.aeruginosa into the liquid.



-16-

Trial Description	Weight of Hexifoam Used (g)	Exposure Time (sec)
Recovery Control	0	0
Test 1	1	30
Test 2	2	30
Test 3	2	60

ResultsRecovery Control

Culture Count onto Hands Total Cells	Control Recovery Total Cells	Volunteer	% Recovery Volunteer	Geo- metric Mean % Recov-
	1	2	1 2	
2.8×10^9	5.5×10^6	21.0×10^6	0.196 0.750	0.384

0.384% is used to calculate the expected recovery in all Hexifoam trials. This adjusts for culture variation and is needed to calculate reductions achieved.

Hexifoam Trials

Trial Description	Culture Count onto Hands Total Cells (y)	Recovery Total Cells Volunteer
		1 2
1 g 30 Sec	3.1×10^9	1.3×10^6 3.2×10^6
2 g 30 Sec	2.6×10^9	5.0×10^5 5.5×10^5
2 g 60 Sec	4.3×10^9	2.55×10^4 11.5×10^4



-17-

Trial Description	Geometric mean Recovery	Calculated Recovery 0.384% x y	Mean Log Reduction	Kill
1 g 30 Sec	2.03×10^6	11.9×10^6	0.768	82.95
2 g 30 Sec	5.24×10^5	10.0×10^6	1.281	94.76
2 g 60 Sec	5.4×10^4	16.5×10^6	2.485	99.67

The foamable compositions within the present invention improve over prior chlorhexidine products commercially available as follows:-

(1) As a pressurised aerosol the pack cannot become internally contaminated.

(2) The aerosol cannot spill and therefore represents no fire hazard.

(3) The foam, as dispensed, is very hard to ignite and will not readily burn as does a spray, presenting a much reduced hazard.

(4) The foam is easily handled and does not allow any waste due to overspray.

(5) The foam as developed is of a fast breaking variety. When applied to the skin it is a stable lump, but body heat or friction cause it to melt and spread onto the skin in a unique, controllable, and fast dispersing manner.

(6) The shelf life of the aerosol is good and with some formulation is probably in excess of five years almost irrespective of the storage environment.

(7) Since a ball of foam can be held in one hand the pack only needs to be touched once and the treated hands never need to come into contact with it.

Quite unexpectedly, having regard to the prior research carried out the stated combination has in testing exceed performance expectation. Further, as disclosed initial microbiological tests have shown the compositions retain the full broad spectrum of activity of chlorhexidine



-18-

and to be surprisingly fast acting, killing 99% plus of M.R.S.A. in less than sixty seconds. This result is clearly superior to conventional chlorhexidine compositions.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A biocidal composition comprising:
 - (a) an alcoholic chlorhexidine solution
 - (b) from .1 to 20% w/w of a quick breaking foaming agent
 - (c) from 3 to 30% w/w of an aerosol propellant and optionally
 - (d) a corrosion inhibitor
2. The composition of claim 1 wherein the chlorhexidine solution is present in amounts from .1 to 10% w/w.
3. The composition of claim 1 wherein the chlorexidine solution is in the form of a gluconate, diacetate hydro chloride or mixtures thereof.
4. The composition of claim 1 wherein the foaming agent comprises an aliphatic alcohol, water, a fatty alcohol and a surface active agent.
5. The composition of claim 4 wherein the aliphatic alcohol is present in amounts of from 40 - 90% ww, water is present in amounts from 10 - 40% w/w, the fatty alcohol is present in amounts of from 0.5 - 10% w/w and the ethoxylated sorbitan ester is present in amounts of from 0.1 - 15% w/w.
6. The composition of claim 4 wherein the aliphatic alcohol is selected from the group including methanol, ethanol, isopropanol and butanol and mixtures thereof.
7. The composition of claim 4 wherein the fatty alcohol is selected from the group including cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, palmityl alcohol and mixtures thereof.



-20-

8. The composition of claim 4 wherein the surface active agent is selected from the group including ethoxylated sorbitan stearate, palmitate, oleate, nonyl phenol ethoxylates, fatty alcohol ethoxylates and mixtures thereof.

9. The composition of claim 1 wherein the propellant is selected from the group including propane, butane, dichlorodifluoro methane, dichloro tetra fluoro ethane, octafluoro cyclo butane and mixtures thereof.

10. The composition of claim 1 wherein the corrosion inhibitor is present in amounts of from .1 - 15% wt.

11. The composition of claim 1 wherein the corrosion inhibitor is an organic acid salt.

12. The composition of claim 11 wherein the organic acid salt is selected from the group including sorbic acid benzoic acid, mixtures thereof and soluble forms thereof.

13. The composition of claim 12 wherein the organic acid is present in an amount of from 0.1 to 3% w/w.

14. The composition of claim 1 further including an emollient.

15. The composition of claim 13 wherein the emolient is selected from the group including lanolin, polyols selected from the group including glycerol, propylene glycol, sorbitol and low molecular weight polymers thereof, vinyl alcohol and polyvinyl pyrrolidone.

16. A biocidal composition comprising:

- (a) 0.1 to 10% w/w of chlorhexidine
- (b) 0.1 to 20% w/w of a quick breaking foam



-21

comprising

- (1) 40 to 90% ww of an aliphatic alcohol
- (2) 0.5 to 10% ww of a fatty alcohol
- (3) 10 to 40% ww water

and

- (4) 0.1 to 15% ww of an ethoxylated sorbitan ester

- (c) 3 to 30% w/w of an aerosol propellant and optionally
- (d) 0.1 - 15% corrosion inhibitor.



INTERNATIONAL SEARCH REPORT

International Application No PCT/AU84/00215

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³ According to International Patent Classification (IPC) or to both National Classification and IPC <div style="text-align: center; font-size: 1.2em; margin-top: 10px;">INT. CL³ A61K 31/155</div>						
II. FIELDS SEARCHED <div style="text-align: center; font-size: 0.8em; margin-top: 5px;">Minimum Documentation Searched ⁴</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <th style="width: 20%; font-size: 0.8em;">Classification System</th> <th style="font-size: 0.8em;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px; vertical-align: top;"> IPC US CL </td> <td style="padding: 5px; vertical-align: top;"> A61K 31/15, A61K 27/00, A01n 47/44 424/45, 424/47 </td> </tr> </table> <div style="text-align: center; font-size: 0.8em; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵</div>			Classification System	Classification Symbols	IPC US CL	A61K 31/15, A61K 27/00, A01n 47/44 424/45, 424/47
Classification System	Classification Symbols					
IPC US CL	A61K 31/15, A61K 27/00, A01n 47/44 424/45, 424/47					
<div style="font-size: 1.2em; margin-bottom: 10px;">AU : AUSTRALIAN CLASSIFICATION 87.16-0</div>						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴						
Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸				
A	AU, B, 51132/73 (472449)(UNILEVER LIMITED) 18 July 1974 (18.07.74) See Page 8					
A	AU, A, 10754/70 (MEDILINE AG) 12 August 1971 (12.08.71) See Pages 12-14					
A	AU, A, 65156/69 (MEDILINE AG) 17 June 1971 (17.06.71) See Page 12					
<div style="font-size: 0.8em;"> <p>* Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search ¹ <div style="text-align: center; font-size: 1.1em; margin-top: 10px;">25 January 1985 (25.01.85)</div>		Date of Mailing of this International Search Report ² <div style="text-align: center; font-size: 1.1em; margin-top: 10px;">30.01.85 30 JANUARY 1985</div>				
International Searching Authority ¹ <div style="text-align: center; font-size: 1.1em; margin-top: 10px;">Australian Patent Office</div>		Signature of Authorized Officer ¹⁰ <div style="text-align: center; margin-top: 10px;">R. DALBON </div>				

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 84/00215

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document
Cited in Search
Report

Patent Family Members

AU 65156/69	BR 6915170 ES 374808 NL 6919223	CH 544548 FR 2026873	DE 1964539 GB 1296360
AU 10754/70	BE 745339 FR 2033831	DE 2004610 GB 1304682	ES 376140
AU 51132/73	AR 193183 CA 1003333 FR 2168463 IT 1009022 NL 7300718	BE 794067 CH 572741 GB 1409533 JP 48080744 US 3949066	BR 7300449 DE 2301829 IN 138618 LU 66835 ZA 730352

END OF ANNEX